PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30421459-7	2019	The level of E6 directly correlated with the extent of cisplatin sensitivity and was shown to be increased in newly established drug-resistant cell line variants, while reducing E6 expression using Brd4-inhibitors enhanced chemoresponse when co-delivered with cisplatin.	Cisplatin	260-269	bromodomain containing 4	Homo sapiens	198-202	
30421459-8	2019	Inhibition of Brd4 could represent a new therapeutic option by increasing treatment response in cervical cancer cells and might allow lower cisplatin dosages, thus reducing negative side effects.	Cisplatin	140-149	bromodomain containing 4	Homo sapiens	14-18	
35167374-0	2022	BRD4 promotes the migration and invasion of bladder cancer through the Sonic hedgehog signaling pathway and enhances cisplatin resistance.	Cisplatin	117-126	bromodomain containing 4	Homo sapiens	0-4	
35167374-6	2022	We further found that cisplatin (DDP) suppressed the migration and invasion of BCa cells in vitro and inhibited tumor growth in vivo; however overexpression of BRD4 weakened the pharmacological effects of DDP.	Cisplatin	22-31	bromodomain containing 4	Homo sapiens	160-164	
35083874-7	2022	RESULTS: BRD4 inhibitors JQ1 and ARV-771 were identified as the most promising drugs both in the cisplatin and radiation screening projects in two NSCLC cell lines.	Cisplatin	97-106	bromodomain containing 4	Homo sapiens	9-13	
35403781-5	2022	Gene expression of HDAC1, HDAC2, SIRT1, MTA1, KAT2B, KAT6A, KAT6B, and BRD4 indicated the cisplatin activates the epigenetic machinery.	Cisplatin	90-99	bromodomain containing 4	Homo sapiens	71-75